课题基金 / 基金详情

PHASE I/II OPEN LABEL, RISING DOSE STUDY OF INTRATHECAL SNX 111

PHASE I/II OPEN LABEL, RISING DOSE STUDY OF INTRATHECAL SNX 111
鞘内 SNX 111 的 I/II 期开放标签、剂量上升研究
批准号：
5220284
负责人：
KIM J BURCHIEL
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5220284
关键词：
calcium channel blockers clinical research clinical trial phase I drug interactions drug screening /evaluation human subject neurotransmitter transport

项目摘要

项目成果

KIM J BURCHIEL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
SNX-111 is a new voltage-sensitive calcium channel blocker that specifically blocks neuronal (N-type) calcium channels. These channels are found in highest density within the substantia gelatinosa of the dorsal horn, where blockage of calcium influx has been shown to create analgesia. The presumed mechanism of action of SNX-111 is the blockage of N-type calcium channels which in turn modulates neurotransmitter release.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EFFICACY OF SUBTHALAMIC VERSUS PALLIDAL STIMULATION IN PARKINSON'S DISEASE
Efficacy of Subthalamic versus Pallidal Stimulation in Parkinson's Disease
EFFICACY OF DEEP BRAIN STIMULATION IN PARKINSONS DISEASE
A PHASE II/III STUDY OF SNX-111 FOR NONMALIGNANT PAIN
海外基金